Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22,279 | $22,680 | $19,572 | $17,199 |
| G&A Expenses | $7,707 | $6,816 | $7,536 | $6,322 |
| SG&A Expenses | $7,707 | $6,816 | $7,536 | $6,322 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $29,986 | $29,496 | $27,108 | $23,521 |
| Operating Income | -$29,986 | -$29,496 | -$27,108 | -$23,521 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,061 | $2,764 | $3,045 | $3,541 |
| Pre-Tax Income | -$26,925 | -$26,732 | -$24,063 | -$19,980 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,925 | -$26,732 | -$24,063 | -$19,980 |
| % Margin | – | – | – | – |
| EPS | -0.71 | -0.75 | -0.12 | -0.1 |
| % Growth | 5.3% | -525% | -20% | – |
| EPS Diluted | -0.71 | -0.75 | -0.12 | -0.1 |
| Weighted Avg Shares Out | 379,312 | 354,446 | 192,881 | 192,881 |
| Weighted Avg Shares Out Dil | 379,312 | 354,446 | 192,881 | 192,881 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,061 | $2,764 | $3,045 | $3,541 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $256 | $252 | $244 | $260 |
| EBITDA | -$26,669 | -$29,244 | -$26,864 | -$23,261 |
| % Margin | – | – | – | – |